For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
|
| Basic information |
| Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
| Wang Chien-Chih |
Yen Lin-Chuan |
Hank Chen |
02-25042121 |
8F-3, No.206, Sec. 2, Nanking E. Rd.,Taipei City 104, Taiwan (R.O.C.) |
2018/06/27 |
| Industrycategory |
Key businesses |
| Biotechnology and Medical Care |
Anxo pharmaceutical, founded in 2003, is a technology based specialty pharmaceutical company aimed on the development and commercialization of all kinds of potential pharmaceutical generic products.
Based on experienced expertise and creativity, Anxo pharmaceutical has successfully developed a serial products spanning fields of DM, CV, CNS, infection, respiratory, GI, ophthalmic, otic and dermatological. Thus far, Anxo has granted 41 ANDAs approval of which includes 13 bioequivants. Anxo’s goal is to become an all-oriented drug developing company in providing more affordable products to consumers as well as expertise service to industry. |
| Financial data |
| Cash flows statement
| Item
|
|
|
| Amount(NTD, in thousands) |
| Cash flows from operating activities |
|
|
| Cash flows from investing activities |
|
|
| Cash flows from financing activities |
|
|
Consolidated/Individual
balance sheet
|
Current assets |
|
|
| Non-current assets |
|
|
| Total assets |
|
|
| Current liabilities |
|
|
| Non-current liabilities |
|
|
| Total liabilities |
|
|
| Share capital |
|
|
| Capital surplus |
|
|
| Retained earnings |
|
|
| Other equity interest |
|
|
| Treasury shares |
|
|
| Total equity attributable to owners of parent |
|
|
| Non-controlling interests |
|
|
| Total equity |
|
|
| Book Value per share(NT$) |
|
|
Consolidated/Individual
profit and loss
statement |
Operating revenue |
|
|
| Operating costs |
|
|
| Gross profit from operations |
|
|
| Operating expenses |
|
|
| Net other income (expenses) |
|
|
| Net operating income |
|
|
| Non-operating income and expenses |
|
|
| Profit before tax |
|
|
| Tax expense |
|
|
| Profit from continuing operations |
|
|
| Profit from discontinued operations |
|
|
| Profit |
|
|
| Other comprehensive income |
|
|
| Comprehensive income |
|
|
| Basic earnings per share |
|
|
 Auditor's report on latest financial statements： auditor's report：
|
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|
